

Figure 1

FIGURE 2


Analysis of Thymosin β16 staining
<10%
10-75%
>75%
Negative
Partial
Positive
Gleason score
10
9
8
7
6
5
4
BPH


Cell Line →
Phenotype →
Dunning Bx
L H
LNCaP
L H
DU

PC3M
P H L
MDA-MB
231
P(L) P(H)
435
L H
Tβ4
Tβ10
Tβ15
Tβ16
β-actin

Figure 3


A
B
C
1 2 3 4 5 6 7 8
A B C D E F G H
A whole brain | amygdala | | | cerebral nucleus | caudate putamen | cerebellum | cerebral cortex | frontal lobe | hippocampus | medulla oblongata
B pituitary | pituitary | | | hypothalamus | olfactory lobe | temporal lobe | thalamus | sub-thalamic nucleus | spinal cord | -
C heart | aorta | | | abdominal muscle | pancreas | pituitary gland | bladder | adrenal gland | pituitary gland | stomach
D testis | ++ ovary | | | prostate | small intestine | colon | spleen | thymus | peripheral leukocyte | lymph node | +++ fetal lung | +++ human DNA 100 ng | +++ human DNA 300 ng
E kidney | liver | | | trachea | placenta | fetal liver | ++++ fetal DNA 100 ng | Poly dA | 100 ng | human C$_0$t DNA 600 ng | +++++ human DNA 900 ng
F spinal cord | + lung | | | ++ fetal kidney | E.coli DNA 100 ng | fetal spleen | 100 ng | + fetal thymus | | | |
G +++ fetal brain | fetal heart | | | yeast DNA 100 ng | | | | | | | |
H yeast total RNA 100 ng | | | | | | | | | | | |

Figure 4

Tβ16 expression increases in the following tumors

	Protein	mRNA/cDNA			
	Ab[a]	EST[b]	SAGE[c]	Array[d]	NB[e]
Prostate carcinoma	+	+	+	+	+
Lung carcinoma	+	+			
Breast carcinoma	+	+	+		+
Thyroid carcinoma	+				
Brain cancers (cerebellum, medulloblastoma, astrocytoma, ependymoma, glioblastoma)		+	+		
Retinoblastoma Eye cancer		+			
Rhabdosarcoma (muscle)		+			
Pancreatic carcinoma	+		+		
Lymphoma (T or B cell)	+	+			
Stomach carcinoma		+			
Ovarian carcinoma			+		

a Antibody detection of protein (western blot or immunohistochemistry)
b Express sequence tag analysis (cDNA)
c Serial Analysis of Gene Expression (cDNA)
d Gene chip array (cRNA/cDNA)
e Northern blot Analysis (RNA)

Figure 5


Heart
Brain
Placenta
Lung
Liver
Skeletal muscle
Kidney
Pancreas
Tβ4
Tβ16
β-actin

figure 6.